Press-release for stocks related to therapeutics

Prices are updated after-hours

tags : Therapeutics crawled date : 2022 - 08 - 04

save search

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results
Published: 2022-08-04 (Crawled : 23:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -6.82% | O: 1.09% H: 0.0% C: 0.0%
SGMO | $0.4853 -5.95% -6.33% 1.7M

Health Technology

| -89.17% | O: -0.42% H: 0.63% C: -0.21%
therapeutics results

Repare Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
Published: 2022-08-04 (Crawled : 22:00) - biospace.com/
RPTX 4 | $3.025 -5.76% -6.12% 140K

Health Technology

| -75.84% | O: 0.96% H: 5.07% C: 4.04%
therapeutics update results

Trevi Therapeutics to Report Q2 2022 Financial Results and Provide a Corporate Update on August 11, 2022
Published: 2022-08-04 (Crawled : 22:00) - prnewswire.com
TRVI | $2.68 3.88% 3.73% 180K

Health Technology

| -25.9% | O: -3.58% H: 13.71% C: 11.71%
report therapeutics update results

Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Published: 2022-08-04 (Crawled : 21:00) - ir.akerotx.com
PFE A | $25.39 -0.12% -0.12% 36M

Health Technology

| -49.02% | O: -0.44% H: 0.66% C: -0.75%
HTGC F | $18.25 0.5% 0.0% 590K

Finance

| 16.56% | O: 0.13% H: 2.69% C: 2.69%
AKRO | $20.535 -4.93% -5.19% 760K

Health Technology

| 60.36% | O: 1.33% H: 6.94% C: 6.33%
therapeutics update results

TG THERAPEUTICS INC. Company News: Berger Montague Investigates Securities Fraud Allegations Against TG Therapeutics Inc. (NASDAQ: TGTX); Lead Plaintiff Deadline is September 16 2022
Published: 2022-08-04 (Crawled : 21:00) - prnewswire.com
TGTX | News | $14.0 1.3% 1.29% 3.5M

Health Technology

| 116.9% | O: -3.26% H: 0.32% C: -0.16%
therapeutics deadline

Marker Therapeutics Announces FDA Clearance of IND for MT-601, the six-antigen targeted T Cell Therapy for the treatment of relapsed/refractory Non-Hodgkin Lymphoma
Published: 2022-08-04 (Crawled : 21:00) - globenewswire.com
MRKR | $4.24 -1.62% -1.65% 13K

Consumer Services

| 30.61% | O: 81.82% H: 10.0% C: -10.0%
mt-601 treatment fda clearance therapeutics therapy

Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results
Published: 2022-08-04 (Crawled : 20:00) - ir.voyagertherapeutics.com
VYGR | $7.55 -2.46% -2.52% 1M

Health Technology

| 1.07% | O: -0.94% H: 0.0% C: -6.35%
therapeutics results

Immune Therapeutics Appoints Chief Financial Officer and Chief Operating Officer
Published: 2022-08-04 (Crawled : 18:00) - globenewswire.com
IMUN | $0.093 214.52% 1.8K

Manufacturing

| Email alert Add to watchlist
therapeutics

Gain Therapeutics to Participate at the 2022 BTIG Biotechnology Conference
Published: 2022-08-04 (Crawled : 17:00) - biospace.com/
GANX | $3.15 -0.94% -0.95% 78K

Professional, Scientific, and T...

| -22.63% | O: 3.41% H: 0.0% C: -6.59%
conference therapeutics

Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma
Published: 2022-08-04 (Crawled : 17:00) - biospace.com/
RAIN | $1.21 0.0% 3.7M

Manufacturing

| -82.1% | O: 1.48% H: 3.5% C: 3.5%
trial therapeutics

UPDATE -- Rain Therapeutics Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma
Published: 2022-08-04 (Crawled : 15:00) - globenewswire.com
RAIN | $1.21 0.0% 3.7M

Manufacturing

| -82.1% | O: 1.48% H: 3.5% C: 3.5%
trial therapeutics update

Regulus Therapeutics Announces Timing for Second Quarter 2022 Financial Results Webcast and Conference Call
Published: 2022-08-04 (Crawled : 14:00) - biospace.com/
RGLS | $2.22 -5.13% -5.41% 200K

Health Technology

| 48.99% | O: 8.05% H: 8.7% C: 5.59%
conference therapeutics

DiaMedica Therapeutics to Report Second Quarter 2022 Financial Results and Provide a Business Update August 11, 2022
Published: 2022-08-04 (Crawled : 14:00) - biospace.com/
DMAC | $2.45 -5.77% -6.12% 17K

Health Technology

| 53.73% | O: -0.62% H: 6.25% C: 6.25%
report therapeutics update results

Lineage Cell Therapeutics to Report Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022
Published: 2022-08-04 (Crawled : 14:00) - biospace.com/
LCTX | $1.2 -6.98% 0.0% 1M

Health Technology

| -20.86% | O: 1.23% H: 8.48% C: 7.27%
report therapeutics update results

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema
Published: 2022-08-04 (Crawled : 13:00) - biospace.com/
ATXS | $10.56 0.1% 0.09% 320K

Manufacturing

| 156.35% | O: 3.23% H: 2.46% C: 1.57%
star-0215 treatment antibody trial therapeutics hereditary angioedema

Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022
Published: 2022-08-04 (Crawled : 13:00) - biospace.com/
VIRI | $0.433 -3.97% -4.13% 59K

Health Technology

| -93.53% | O: -1.97% H: 3.04% C: 2.75%
report therapeutics update results

Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
Published: 2022-08-04 (Crawled : 13:00) - biospace.com/
DYN | $23.65 -4.71% -4.95% 980K

Health Technology

| 124.52% | O: -1.73% H: 7.49% C: 4.92%
therapeutics results

Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
Published: 2022-08-04 (Crawled : 13:00) - biospace.com/
REGN | $893.66 -0.84% -0.84% 450K

Health Technology

| 48.03% | O: -1.01% H: 3.43% C: 2.04%
NTLA | $21.3 -0.93% -0.94% 1.1M

Health Technology

| -70.26% | O: -13.67% H: 6.45% C: 5.7%
therapeutics results

Edgewise Therapeutics Reports Second Quarter 2022 Financial Results
Published: 2022-08-04 (Crawled : 13:00) - biospace.com/
EWTX | $15.43 -1.41% -1.43% 530K

Manufacturing